188 related articles for article (PubMed ID: 36813928)
21. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Reardon DA; Herndon JE; Peters KB; Desjardins A; Coan A; Lou E; Sumrall AL; Turner S; Lipp ES; Sathornsumetee S; Rich JN; Sampson JH; Friedman AH; Boulton ST; Bigner DD; Friedman HS; Vredenburgh JJ
Br J Cancer; 2012 Oct; 107(9):1481-7. PubMed ID: 23037712
[TBL] [Abstract][Full Text] [Related]
22. [Single center experience with bevacizumab in a cohort of patients treated for a relapsing glioblastoma].
Mbagui R; Ricard D; Vallard A; Magne N; Dulou R; Lahutte M; Calcina P; Taillia H; Yordanova Y; Delmas JM; Bauduceau O; Chargari C
Presse Med; 2016 May; 45(5):e131-8. PubMed ID: 26916405
[TBL] [Abstract][Full Text] [Related]
23. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
24. Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab.
Liau CT; Chou WC; Wei KC; Chang CN; Toh CH; Jung SM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e8-e14. PubMed ID: 28792121
[TBL] [Abstract][Full Text] [Related]
25. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
29. [The effect of bevacizumab monotherapy on progression free survival in recurrent glioblastoma].
Czigléczki G; Sinkó D; Benkő Z; Bagó A; Fedorcsák I; Sipos L
Ideggyogy Sz; 2019 May; 72(5-6):153-158. PubMed ID: 31241258
[TBL] [Abstract][Full Text] [Related]
30. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC; Kim BT
J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
[TBL] [Abstract][Full Text] [Related]
32. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
33. Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Moon HH; Park JE; Kim YH; Kim JH; Kim HS
J Neurooncol; 2022 May; 157(3):405-415. PubMed ID: 35275335
[TBL] [Abstract][Full Text] [Related]
34. Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Carvalho B; Lopes RG; Linhares P; Costa A; Caeiro C; Fernandes AC; Tavares N; Osório L; Vaz R
J Neurooncol; 2020 Mar; 147(1):109-116. PubMed ID: 31974803
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
37. Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early
Pasqualetti F; Gonnelli A; Molinari A; Cantarella M; Montrone S; Cristaudo A; Baldaccini D; Mattioni R; Delishaj D; Mazzotti V; Morganti R; Cocuzza P; Fabrini MG; Lombardi G; Rudà R; Soffietti R; Paiar F
Anticancer Res; 2018 Oct; 38(10):5877-5881. PubMed ID: 30275213
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
39. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
Kurokawa R; Baba A; Kurokawa M; Capizzano A; Hassan O; Johnson T; Ota Y; Kim J; Hagiwara A; Moritani T; Srinivasan A
AJNR Am J Neuroradiol; 2022 Feb; 43(2):202-206. PubMed ID: 35058300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
